Cochlear Limited Logo

Cochlear Limited

COH.AX

(2.5)
Stock Price

293,26 AUD

15.55% ROA

19.7% ROE

53.96x PER

Market Cap.

19.205.117.130,00 AUD

13.24% DER

1.39% Yield

15.8% NPM

Cochlear Limited Stock Analysis

Cochlear Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Cochlear Limited Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (17.75%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

3 DER

The stock has a low debt to equity ratio (15%), which means it has a small amount of debt compared to the ownership it holds

4 Dividend

The company's consistent dividend distribution over the past five years reflects its dedication to providing shareholders with steady returns, making it an appealing choice for investors seeking income stability.

5 Dividend Growth

The company's dividend growth has been consistently strong over the past three years, with annual increases that demonstrate its commitment to rewarding shareholders.

6 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (599), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

7 PBV

The stock's high Price-to-Book Value (P/BV) ratio (10.13x) suggests it's overvalued, potentially making it an expensive investment.

8 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

10 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

11 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

Cochlear Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Cochlear Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Buy

Cochlear Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Cochlear Limited Revenue
Year Revenue Growth
1996 72.275.000
1997 72.923.000 0.89%
1998 0 0%
1999 0 0%
2000 0 0%
2001 220.111.000 100%
2002 254.981.000 13.68%
2003 288.576.000 11.64%
2004 282.774.000 -2.05%
2005 344.854.000 18%
2006 452.260.000 23.75%
2007 559.412.000 19.15%
2008 601.725.000 7.03%
2009 694.699.000 13.38%
2010 734.803.000 5.46%
2011 809.646.000 9.24%
2012 778.996.000 -3.93%
2013 752.721.000 -3.49%
2014 804.936.000 6.49%
2015 925.630.000 13.04%
2016 1.130.552.000 18.13%
2017 1.253.800.000 9.83%
2018 1.363.700.000 8.06%
2019 1.426.700.000 4.42%
2020 1.320.600.000 -8.03%
2020 1.352.300.000 2.34%
2021 1.493.300.000 9.44%
2022 1.641.100.000 9.01%
2023 1.955.700.000 16.09%
2024 4.579.200.000 57.29%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Cochlear Limited Research and Development Expenses
Year Research and Development Expenses Growth
1996 11.015.000
1997 10.633.000 -3.59%
1998 0 0%
1999 0 0%
2000 0 0%
2001 27.742.000 100%
2002 42.977.000 35.45%
2003 37.030.000 -16.06%
2004 44.452.000 16.7%
2005 43.760.000 -1.58%
2006 58.926.000 25.74%
2007 65.949.000 10.65%
2008 78.374.000 15.85%
2009 96.498.000 18.78%
2010 94.881.000 -1.7%
2011 108.935.000 12.9%
2012 119.322.000 8.71%
2013 124.715.000 4.32%
2014 127.562.000 2.23%
2015 127.985.000 0.33%
2016 145.080.000 11.78%
2017 151.900.000 4.49%
2018 167.700.000 9.42%
2019 184.400.000 9.06%
2020 185.100.000 0.38%
2020 185.100.000 0%
2021 195.000.000 5.08%
2022 210.700.000 7.45%
2023 244.900.000 13.96%
2024 598.800.000 59.1%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Cochlear Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
1996 0
1997 1.764.000 100%
1998 0 0%
1999 0 0%
2000 0 0%
2001 15.435.000 100%
2002 10.665.000 -44.73%
2003 17.956.000 40.6%
2004 21.003.000 14.51%
2005 33.127.000 36.6%
2006 29.951.000 -10.6%
2007 38.635.000 22.48%
2008 36.092.000 -7.05%
2009 44.979.000 19.76%
2010 43.722.000 -2.87%
2011 43.699.000 -0.05%
2012 45.429.000 3.81%
2013 38.157.000 -19.06%
2014 44.162.000 13.6%
2015 59.536.000 25.82%
2016 79.287.000 24.91%
2017 85.200.000 6.94%
2018 97.400.000 12.53%
2019 94.800.000 -2.74%
2020 93.800.000 -1.07%
2020 93.800.000 0%
2021 116.100.000 19.21%
2022 159.000.000 26.98%
2023 203.900.000 22.02%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Cochlear Limited EBITDA
Year EBITDA Growth
1996 13.731.000
1997 14.964.000 8.24%
1998 18.100.000 17.33%
1999 26.787.000 32.43%
2000 33.830.000 20.82%
2001 46.673.000 27.52%
2002 56.927.000 18.01%
2003 88.553.000 35.71%
2004 61.668.000 -43.6%
2005 93.457.000 34.01%
2006 131.554.000 28.96%
2007 174.759.000 24.72%
2008 172.757.000 -1.16%
2009 187.824.000 8.02%
2010 227.910.000 17.59%
2011 250.536.000 9.03%
2012 161.677.000 -54.96%
2013 196.402.000 17.68%
2014 173.517.000 -13.19%
2015 228.562.000 24.08%
2016 277.047.000 17.5%
2017 338.100.000 18.06%
2018 371.800.000 9.06%
2019 382.200.000 2.72%
2020 -260.600.000 246.66%
2020 336.500.000 177.44%
2021 404.300.000 16.77%
2022 434.700.000 6.99%
2023 493.300.000 11.88%
2024 1.180.000.000 58.19%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Cochlear Limited Gross Profit
Year Gross Profit Growth
1996 72.275.000
1997 72.923.000 0.89%
1998 0 0%
1999 0 0%
2000 0 0%
2001 147.692.000 100%
2002 182.015.000 18.86%
2003 223.473.000 18.55%
2004 206.901.000 -8.01%
2005 253.603.000 18.42%
2006 321.551.000 21.13%
2007 399.952.000 19.6%
2008 435.087.000 8.08%
2009 500.976.000 13.15%
2010 538.748.000 7.01%
2011 587.893.000 8.36%
2012 580.575.000 -1.26%
2013 546.131.000 -6.31%
2014 556.651.000 1.89%
2015 650.310.000 14.4%
2016 796.959.000 18.4%
2017 895.400.000 10.99%
2018 1.002.500.000 10.68%
2019 1.075.600.000 6.8%
2020 976.200.000 -10.18%
2020 1.007.900.000 3.15%
2021 1.083.100.000 6.94%
2022 1.230.100.000 11.95%
2023 1.467.700.000 16.19%
2024 3.474.000.000 57.75%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Cochlear Limited Net Profit
Year Net Profit Growth
1996 10.863.000
1997 10.809.000 -0.5%
1998 13.285.000 18.64%
1999 16.327.000 18.63%
2000 20.167.000 19.04%
2001 31.178.000 35.32%
2002 40.110.000 22.27%
2003 58.213.000 31.1%
2004 627.000 -9184.37%
2005 1.168.000 46.32%
2006 80.032.000 98.54%
2007 100.131.000 20.07%
2008 115.234.000 13.11%
2009 130.540.000 11.73%
2010 155.152.000 15.86%
2011 180.114.000 13.86%
2012 56.803.000 -217.09%
2013 132.563.000 57.15%
2014 93.709.000 -41.46%
2015 145.840.000 35.75%
2016 188.921.000 22.8%
2017 223.616.000 15.52%
2018 245.800.000 9.03%
2019 276.700.000 11.17%
2020 -238.300.000 216.11%
2020 -238.300.000 0%
2021 326.500.000 172.99%
2022 289.100.000 -12.94%
2023 300.600.000 3.83%
2024 661.600.000 54.56%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Cochlear Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 1 0%
2002 1 0%
2003 1 100%
2004 1 0%
2005 1 100%
2006 1 0%
2007 2 0%
2008 2 50%
2009 2 0%
2010 3 0%
2011 3 33.33%
2012 1 -200%
2013 2 50%
2014 2 -100%
2015 3 50%
2016 3 33.33%
2017 4 0%
2018 4 25%
2019 5 0%
2020 -4 200%
2020 -4 0%
2021 5 200%
2022 4 0%
2023 5 0%
2024 10 60%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Cochlear Limited Free Cashflow
Year Free Cashflow Growth
1996 17.904.000
1997 4.204.000 -325.88%
1998 11.957.000 64.84%
1999 21.484.000 44.34%
2000 5.301.000 -305.28%
2001 14.224.000 62.73%
2002 -16.232.000 187.63%
2003 68.318.000 123.76%
2004 35.638.000 -91.7%
2005 87.194.000 59.13%
2006 36.341.000 -139.93%
2007 50.060.000 27.41%
2008 55.398.000 9.64%
2009 106.647.000 48.05%
2010 87.173.000 -22.34%
2011 110.763.000 21.3%
2012 130.836.000 15.34%
2013 19.308.000 -577.63%
2014 87.920.000 78.04%
2015 164.804.000 46.65%
2016 156.255.000 -5.47%
2017 206.300.000 24.26%
2018 229.700.000 10.19%
2019 236.100.000 2.71%
2020 -288.300.000 181.89%
2021 198.699.999 245.09%
2022 299.300.000 33.61%
2023 266.500.000 -12.31%
2024 184.600.000 -44.37%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Cochlear Limited Operating Cashflow
Year Operating Cashflow Growth
1996 19.478.000
1997 6.233.000 -212.5%
1998 14.252.000 56.27%
1999 25.799.000 44.76%
2000 11.060.000 -133.26%
2001 19.761.000 44.03%
2002 898.000 -2100.56%
2003 78.817.000 98.86%
2004 48.970.000 -60.95%
2005 98.634.000 50.35%
2006 51.555.000 -91.32%
2007 76.836.000 32.9%
2008 84.548.000 9.12%
2009 146.628.000 42.34%
2010 179.546.000 18.33%
2011 201.277.000 10.8%
2012 168.280.000 -19.61%
2013 69.727.000 -141.34%
2014 111.417.000 37.42%
2015 188.701.000 40.96%
2016 185.113.000 -1.94%
2017 259.800.000 28.75%
2018 258.100.000 -0.66%
2019 296.000.000 12.8%
2020 -157.800.000 287.58%
2021 265.399.999 159.46%
2022 376.500.000 29.51%
2023 362.400.000 -3.89%
2024 231.700.000 -56.41%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Cochlear Limited Capital Expenditure
Year Capital Expenditure Growth
1996 1.574.000
1997 2.029.000 22.42%
1998 2.295.000 11.59%
1999 4.315.000 46.81%
2000 5.759.000 25.07%
2001 5.537.000 -4.01%
2002 17.130.000 67.68%
2003 10.499.000 -63.16%
2004 13.332.000 21.25%
2005 11.440.000 -16.54%
2006 15.214.000 24.81%
2007 26.776.000 43.18%
2008 29.150.000 8.14%
2009 39.981.000 27.09%
2010 92.373.000 56.72%
2011 90.514.000 -2.05%
2012 37.444.000 -141.73%
2013 50.419.000 25.73%
2014 23.497.000 -114.58%
2015 23.897.000 1.67%
2016 28.858.000 17.19%
2017 53.500.000 46.06%
2018 28.400.000 -88.38%
2019 59.900.000 52.59%
2020 130.500.000 54.1%
2021 66.700.000 -95.65%
2022 77.200.000 13.6%
2023 95.900.000 19.5%
2024 47.100.000 -103.61%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Cochlear Limited Equity
Year Equity Growth
1996 18.456.000
1997 23.307.000 20.81%
1998 32.095.000 27.38%
1999 34.050.000 5.74%
2000 42.829.000 20.5%
2001 55.495.000 22.82%
2002 75.416.000 26.41%
2003 119.687.000 36.99%
2004 145.529.000 17.76%
2005 165.870.000 12.26%
2006 209.778.000 20.93%
2007 260.809.000 19.57%
2008 319.341.000 18.33%
2009 364.234.000 12.33%
2010 438.308.000 16.9%
2011 503.283.000 12.91%
2012 384.880.000 -30.76%
2013 356.913.000 -7.84%
2014 329.205.000 -8.42%
2015 355.386.000 7.37%
2016 448.557.000 20.77%
2017 543.600.000 17.48%
2018 610.800.000 11%
2019 725.900.000 15.86%
2020 1.401.500.000 48.21%
2021 1.689.600.000 17.05%
2022 1.685.700.000 -0.23%
2023 1.748.800.000 3.61%
2024 1.840.500.000 4.98%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Cochlear Limited Assets
Year Assets Growth
1996 48.242.000
1997 51.287.000 5.94%
1998 69.113.000 25.79%
1999 82.939.000 16.67%
2000 93.771.000 11.55%
2001 129.048.000 27.34%
2002 160.428.000 19.56%
2003 230.579.000 30.42%
2004 264.539.000 12.84%
2005 505.747.000 47.69%
2006 545.924.000 7.36%
2007 585.737.000 6.8%
2008 607.916.000 3.65%
2009 679.373.000 10.52%
2010 751.719.000 9.62%
2011 741.047.000 -1.44%
2012 702.542.000 -5.48%
2013 764.501.000 8.1%
2014 789.036.000 3.11%
2015 875.402.000 9.87%
2016 957.363.000 8.56%
2017 1.136.300.000 15.75%
2018 1.156.900.000 1.78%
2019 1.379.200.000 16.12%
2020 2.583.100.000 46.61%
2021 2.426.100.000 -6.47%
2022 2.465.100.000 1.58%
2023 2.568.700.000 4.03%
2024 2.745.100.000 6.43%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Cochlear Limited Liabilities
Year Liabilities Growth
1996 29.786.000
1997 27.980.000 -6.45%
1998 37.018.000 24.42%
1999 48.889.000 24.28%
2000 50.942.000 4.03%
2001 73.553.000 30.74%
2002 85.012.000 13.48%
2003 110.892.000 23.34%
2004 119.010.000 6.82%
2005 339.877.000 64.98%
2006 336.146.000 -1.11%
2007 324.928.000 -3.45%
2008 288.575.000 -12.6%
2009 315.139.000 8.43%
2010 313.411.000 -0.55%
2011 237.764.000 -31.82%
2012 317.662.000 25.15%
2013 407.588.000 22.06%
2014 459.831.000 11.36%
2015 520.015.999 11.57%
2016 508.806.000 -2.2%
2017 592.700.000 14.15%
2018 546.100.000 -8.53%
2019 653.300.000 16.41%
2020 1.181.600.000 44.71%
2021 736.500.000 -60.43%
2022 779.400.000 5.5%
2023 819.900.000 4.94%
2024 904.600.000 9.36%

Cochlear Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
34.48
Net Income per Share
5.45
Price to Earning Ratio
53.96x
Price To Sales Ratio
8.5x
POCF Ratio
49.52
PFCF Ratio
64.23
Price to Book Ratio
10.46
EV to Sales
8.39
EV Over EBITDA
31.23
EV to Operating CashFlow
48.7
EV to FreeCashFlow
63.33
Earnings Yield
0.02
FreeCashFlow Yield
0.02
Market Cap
19,21 Bil.
Enterprise Value
18,94 Bil.
Graham Number
58.7
Graham NetNet
2.77

Income Statement Metrics

Net Income per Share
5.45
Income Quality
1.09
ROE
0.2
Return On Assets
0.13
Return On Capital Employed
0.25
Net Income per EBT
0.74
EBT Per Ebit
0.93
Ebit per Revenue
0.23
Effective Tax Rate
0.26

Margins

Sales, General, & Administrative to Revenue
0.04
Research & Developement to Revenue
0.12
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.75
Operating Profit Margin
0.23
Pretax Profit Margin
0.21
Net Profit Margin
0.16

Dividends

Dividend Yield
0.01
Dividend Yield %
1.39
Payout Ratio
0.69
Dividend Per Share
4.1

Operating Metrics

Operating Cashflow per Share
5.94
Free CashFlow per Share
4.57
Capex to Operating CashFlow
0.23
Capex to Revenue
0.04
Capex to Depreciation
1.06
Return on Invested Capital
0.18
Return on Tangible Assets
0.16
Days Sales Outstanding
81.14
Days Payables Outstanding
196.88
Days of Inventory on Hand
254.29
Receivables Turnover
4.5
Payables Turnover
1.85
Inventory Turnover
1.44
Capex per Share
1.37

Balance Sheet

Cash per Share
7,84
Book Value per Share
28,10
Tangible Book Value per Share
21.22
Shareholders Equity per Share
28.1
Interest Debt per Share
3.79
Debt to Equity
0.13
Debt to Assets
0.09
Net Debt to EBITDA
-0.45
Current Ratio
2.3
Tangible Asset Value
1,39 Bil.
Net Current Asset Value
0,55 Bil.
Invested Capital
1788800000
Working Capital
0,82 Bil.
Intangibles to Total Assets
0.16
Average Receivables
0,48 Bil.
Average Payables
0,28 Bil.
Average Inventory
356550000
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Cochlear Limited Dividends
Year Dividends Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 1 0%
2003 1 0%
2004 1 0%
2005 1 0%
2006 1 100%
2007 1 0%
2008 2 0%
2009 2 0%
2010 2 50%
2011 2 0%
2012 3 0%
2013 3 33.33%
2014 3 -50%
2015 2 0%
2016 2 0%
2017 3 0%
2018 3 33.33%
2019 3 0%
2020 2 -200%
2021 3 50%
2022 3 33.33%
2023 3 0%
2024 4 25%

Cochlear Limited Profile

About Cochlear Limited

Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. The company was founded in 1981 and is headquartered in Sydney, Australia.

CEO
Mr. Diggory William Howitt BE
Employee
4.996
Address
1 University Avenue
Sydney, 2109

Cochlear Limited Executives & BODs

Cochlear Limited Executives & BODs
# Name Age
1 Ms. Jennifer Stevenson
Vice President of Corporate Communications & Brand
70
2 Mr. Rob McGrory
Group General Counsel & Company Secretary
70
3 Mr. Greg Bodkin BE (Hons), MComm (UNSW)
Senior Vice President of Global Supply Chain
70
4 Mr. Diggory William Howitt BE (Hons), MBA
Chief Executive Officer, MD, President & Executive Director
70
5 Mr. Stuart Sayers
Chief Financial Officer
70
6 Mr. Jan Janssen MSc Elec Eng
Chief Technology Officer
70
7 Ms. Karen O'Driscoll
Chief Information Officer
70
8 Ms. Kristina Devon
Vice President of Investor Relations
70
9 Mr. Dean Phizacklea
Senior Vice President of Global Strategic Marketing
70
10 Ms. Jennifer Hornery
Senior Vice President of Global People & Culture
70

Cochlear Limited Competitors

CSL Limited Logo
CSL Limited

CSL.AX

(2.0)
ResMed Inc. Logo
ResMed Inc.

RMD.AX

(3.5)
Ansell Limited Logo
Ansell Limited

ANN.AX

(2.2)